Cytomegalovirus (CMV) infection
- Treat clinically important CMV disease or high-risk viremia
- Ganciclovir/valganciclovir are core therapies
- Foscarnet/cidofovir for selected resistant/intolerant cases
- Myelosuppression is a major ganciclovir toxicity
- Kidney toxicity limits foscarnet/cidofovir
- Transplant strategy may be prophylaxis or preemptive therapy
Use at a glance
- Treat clinically important CMV disease or high-risk viremia
Escalation / refractory disease
- Ganciclovir/valganciclovir are core therapies
- Transplant strategy may be prophylaxis or preemptive therapy
Choosing treatment
- Foscarnet/cidofovir for selected resistant/intolerant cases
Practical pearls
- Myelosuppression is a major ganciclovir toxicity
- Kidney toxicity limits foscarnet/cidofovir
Self-check
- What should be treated in Cytomegalovirus (CMV) infection?
clinically important CMV disease or high-risk viremia.
Drugs used for this (4)
All clinical uses · Open the interactive console ↗
